|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Psoriasis - Intellectual property drives growth
Datamonitor, July 2009, Pages: 204
The launch of new brands in both biologic and topical treatments in 2009 is shaking up the psoriasis market. Stelara (ustekinumab; Johnson & Johnson) is eagerly anticipated by dermatologists, and Datamonitor forecast strong uptake. However, the threat of biosimilars looms over all biologic therapies.
Scope
- Analysis of the current and future market dynamics in psoriasis across the US, France, Germany, Italy, Spain the UK and Japan
- Assessment of biologic, vitamin derivative, topical corticosteroid and immunomodulator classes
- Psoriasis-specific forecast data for indication scrutiny, but total brand data also included to put sales in context for brand and company
- Scenario forecasts for go/no-go on biosimilar legislation and the impact of possible additional cost containment measures
Highlights of this title
The biologics created $1.4 billion in psoriasis sales in 2008 across the seven major markets, contributing 55% of the $2.5billion psoriasis market. However, the economic downturn resulted in a plateau in biologic sales in psoriasis in 2008. Following a double digit CAGR over the last 4 years, it will slow to 3.4% from 2008 to 2018.
Leo Pharmas Dovobet (calcipotriol + betamethasone) brand dominates the topical class, reaching nearly $0.5billion over the next 10 years. Other molecules are attempting to break into this domain. Galdermas Vectical (calcitriol) launched in February 2009 in the US, but intellectual property challenges are predicted to dampen its potential.
The withdrawal of Genentech/Merck Seronos Raptiva (efalizumab) in Q1 2009 is predicted to benefit both Abbotts Humira (adalimumab) and Johnson & Johnsons Stelara (ustekinumab), but safety will be even more key to regulators now. Dermatologists are particularly eager to use Stelara, and peak psoriasis sales reach $600m in the seven major markets.
Key reasons to purchase this title
- Assess the impact of the economic downturn on psoriasis, which is vulnerable to cost-saving behavior compared to other autoimmune disorders
- Assess the impact of new brands on the market and consider the value to volume ratio for the key classes
- See how psoriasis contributes to total brand sales and company portfolios
|
|
|
|
